Exhibit 99.1
ADMA Biologics Realizing the Potential of Specialty Biologicswith
Groundbreaking Immunotechnology March 2024 NASDAQ: ADMA
Forward-Looking Statements This presentation contains "forward-looking
statements," pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. and its subsidiaries (collectively, “we,” “our” or the “Company”), including, without limitation,
statements that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words “estimate,” “project,” “potential,” “possible,” “forecast,” “intend,” “target,” “anticipate,” “plan,” “expect,”
“believe,” “will,” “is likely,” “will likely,” “should,” “could,” “would,” “may” or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements also include, without limitation, our plans to
develop, manufacture, market, launch and expand our own commercial infrastructure and commercialize our current products and future products; our plans to expand our pipeline with differentiated immune globulin product candidates in
development; potential near and mid-term value creation through certain milestones; the possibility of expanding our product portfolio with additional specialty immune globulin products; product expansions into new fields of use, indications,
target populations and product candidates, and the labeling or nature of any such approvals; our dependence upon our third-party and related party customers and vendors and their compliance with regulatory bodies; our ability to obtain
adequate quantities of U.S. Food and Drug Administration (“FDA”)-approved plasma with proper specifications; the likelihood and timing of FDA action with respect to any further filings by the Company; the expected financial, strategic and
commercial benefits of our FDA- approved SA25 Workcell aseptic fill finish machine; results of clinical development; the potential of specialty plasma-derived biologics to provide meaningful clinical improvement for patients living with
Primary Immune Deficiency Disease (“PI”); expected market size growth in the U.S. immune globulin market; our ability to market and promote our products in the competitive environment and to generate meaningful revenues; our estimated revenue
potential and related timing; certain revenue opportunities; future financial guidance; our estimated revenue growth relative to our competitors; our production capacity and yield and ability to increase such capacity and yield; our ability
to increase market share and grow revenue through anticipated product launches as well as expected peak market share; estimated global supply and demand for plasma; the estimated value of our Boca Raton manufacturing facility; potential
clinical trial initiations; potential investigational new product applications, Biologics License Applications, and expansion plans; our intellectual property position, including our expectations of the scope of patent protection with respect
to our products or other future pipeline product candidates; the achievement of clinical and regulatory milestones; our manufacturing capabilities; third-party contractor capabilities and strategy; our plans relating to manufacturing, supply
and other collaborative agreements; potential contract manufacturing opportunities and sales of our immune globulin products and intermediates; our estimates regarding expenses, capital requirements and needs for additional financing;
possible or likely reimbursement levels for our currently marketed products and estimates regarding market size; projected growth and sales for our existing products as well as our expectations of market acceptance of BIVIGAM® and ASCENIV™;
future economic conditions and performance; commercialization efforts relating to our products and the runway and limitation of our available cash; and our ability to identify alternative sources of cash. The forward-looking statements
contained herein represent the Company’s estimates and assumptions only as of the date of this presentation, and the Company undertakes no duty or obligation to update or revise publicly any forward-looking statements contained in this
presentation, except as otherwise required by the federal securities laws. Forward-looking statements are subject to many risks, uncertainties and other factors that could cause our actual results, and the timing of certain events, to differ
materially from any future results expressed or implied by these forward-looking statements, including, but not limited to, the continued safety and efficacy of, and our ability to obtain and maintain regulatory approvals of, our current
products as well as our plans to increase our supplies of plasma; regulatory processes and interpretations of final data of our products and product candidates; acceptability of any of our products for any purpose, by physicians, patients or
payers; concurrence by the FDA with our conclusions and the satisfaction by us of its guidance the risks; and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Form
10-K, 10-Q and 8-K, and any amendments thereto.
Who We Are: A Specialty Biologics Company ADMA Biologics i4 an end-to-end
commercial biopharmaceutical company committed to manufacturing, marketing and developing specialty biologics for the prevention and treatment of infectious diseases in the immune compromised and other patients at risk for infection 3 ADMA
Biologics is an end-to-end BioPharma company leading the way as a producer of specialtyplasma-derived biologics Three FDA-approved products: ASCENIV™ (Immune Globulin Intravenous, Human–slra) BIVIGAM®(Immune Globulin Intravenous,
Human) NABI-HB®(Hepatitis B Immune Globulin, Human) Intellectual Property: Patents and proven immunotechnology that has forged a new path forward in improving the lives of the immune compromised and other patients at risk for
infection. Contract manufacturing: Full suite of CDMO and contract manufacturing organization (CMO) opportunities. Partner with us for your clinical-stage or commercial aseptic filling, packaging requirements, and our unique good
manufacturing practice (GMP) testing Optimized manufacturingprocesses: Robust, sustainable, and controlled manufacturing process for producing our commercially available plasma-derived products Plasma collection network: 10
state-of-the-art FDA-licensed facilities dedicated to the collection of human plasma equipped with experienced clinicians and credentialed staff for plasma collection and donor care Corporate HeadquartersRamsey, NJ Manufacturing
FacilityBoca Raton, FL 640 Full Time Employees
DIFFERENTIATION VERTICAL INTEGRATION ASSET DURABILITY UPSIDE STRONG BALANCE
SHEET Differentiated U.S. Specialty Biologics Opportunity in a Large and Growing End-Market Vertically Integrated Supply Chain with Innovative Technology and Production Processes Unique Scarcity Value and Asset Durability Potential
Upside Through Pipeline Products and Production Yield Enhancements Strong Balance Sheet and Top Tier Earnings Growth Outlook DIFFERENTIATION – VERTICAL INTEGRATION – IP – ASSET DURABILITY/SCARCITY PIPELINE – YIELD ENHANCEMENT – FORECASTED
GROWTH High Growth, Profitable BioPharma Company Driving Innovation in the Specialty Biologics Market ADMA Investment Highlights
Differentiated Opportunity in a Large & Growing Market One of six
manufacturers in a historically undersupplied U.S. IG market The only fully vertically integrated U.S.-domiciled fractionator Four major producers (Grifols, CSL Behring, Shire and Octapharma) collectively account for >94% of U.S. IG
market Existing competitors are at or near capacity; ADMA is in early stages ofits growth and production ramp-up ADMA is 1 of 6 Manufacturers in a Growing,Supply-Constrained U.S. Immunoglobulin (IG) Market Comprehensive suite of three U.S.
FDA-approved commercial IVIG products: Standard IVIG (BIVIGAM), including a range of vial sizes and configurations Hyperimmune IG portfolio, comprised of ASCENIV and Nabi-HB ASCENIV is a unique IG and the only product in its class
produced by blending normal plasma with hyperimmune plasma using ADMA’s patented methods Nabi-HB protects against HBV infection among newly exposed individuals Three FDA-Approved Products& Six Diversified Revenue Streams U.S. IG
Market: ~$10.5Bn Growing to $20Bn+ Source: The Plasma Proteins Market In The United States 2022, Marketing Research Bureau Inc., October 2022 1 ‘15-22 CAGR 12% ADMA is 1 of 6 Manufacturers in a Growing,Supply-Constrained U.S.
Immunoglobulin (IG) Market
In-House Fill-Finish Functions Vertically Integrated Supply Chain with
Innovative Technology& Production Processes 10 plasma collection facilities FDA licensed Contractually obligated third-party supply agreements expected to supplement the growing internal plasma collections Well-positioned
infrastructure to support near term revenue growth and ensure continuity of product supply into the supply-constrained U.S. IG market End-to-end control of supply chain from plasma collection through plasma fractionation, purification,
fill-finish and testing Among an elite group of U.S.-based biologic drug manufacturers with comprehensive in-house control of critical manufacturing and testing functions Operating in cGMP compliance with validated methods Successful
implementation of supply chain enhancements largely de-risks production scale-up and growth outlook FDA approved In-house aseptic fill-finishing capabilities Ongoing exploration of potentially accretive third-party fill-finish
opportunities SA25 Workcell anticipated to meet all internal production needs with additional idle capacity, potentially adding new third-party revenues Plasma Supply Self-Sufficiency End-to-End Control of Supply
Chain Manufacturing Raw Material Collections Filling & Packaging Release & In-Process Testing 2
Unique Scarcity Value and Asset Durability Capital requirements, regulatory
approvals and manufacturing lead time prohibit manufacturers from quickly increasing output and filling demand in end-market supply Unique and complex manufacturing process with a long production cycle (7-12 months) Market demand forecasted
to outpace industry supply for the foreseeable future Strict regulatory requirements for plasma-derived therapeutics governed by the FDA and state health departments Validation, product registration and ultimate commercialization takes ~3
to 5+ years – all current and complete ADMA operates in cGMP compliance across its manufacturing footprint as per recent FDA inspections and approvals ADMA estimates, based upon publicly disclosed fractionator transactions, Boca Plant
valuation estimated at $400M+ and ~5 years to complete registrations, clinical trials and construction of a cGMP-compliant fractionation plant and fill-finish facility of equivalent capacity to ADMA’s Complex Manufacturing Process Validated
and U.S. FDA Approved Adhere to Strict RegulatoryRequirements With Data,Compliant SOPs and Processes In-Place Significant Scarcity Valuefor ADMA’s Plant ADMA acquires the Boca Raton facility and all rights to BIVIGAM JUNE 2017 ADMA
works diligently to bring manufacturing facility into FDA compliance FDACompliance JULY 2018 ADMA successfully obtains FDA approval for the optimized manufacturing process for BIVIGAM MAY 2019 Source: Wall Street research FDA
Biologics inspection completed; achieved VAI compliance status AUG 2021 FDACompliance 3
Potential Upside Through Production Yield Enhancementsand New Product Pipeline
Program Current plant infrastructure supports well-defined pathway to $380M+ revenues by 2025 Advancing initiative to capture additional IG production yields from same quantities of starting plasma Significant upside potential from
production yield enhancement,if successful Expected to benefit from market share gains as well as end-marketIG growth Issued IP for commercial product to screen hyperimmunedonors, tailor compositions and form plasma pools IP protection
through 2035 Attractive new product and label expansion opportunities for specialty IGs targeting patient populations with high unmet need. S. pneumonia hyperimmune patent estate extends into 2037 Published data supports potential
evaluation of ASCENIV in immune-compromised patients and other respiratory viral pathogens in primary and secondary immune-deficient populations Current Capacity Supports ~$380M+ 2025 Revenue; Upside Potential from Production Yield
Enhancements Potential Hyperimmune Globulin Pipeline Expansion ADMA’s Patented Immunotechnology 4 Screen and identify high-titer RSV plasma donors Hyperimmune donors with sufficient antibodies to select pathogens are
identified Tailoredcompositions Tailored plasma poolsare derived from a unique blend of normal source plasma and plasma obtained from the selected donors Proprietarytesting A proprietary microneutralization assay quantitatively measures
titer levels of neutralizing RSV antibodies in plasma donor samples
Strong Balance Sheet & Top Tier Earnings Growth Outlook Strong Balance
Sheet Supports Capital Allocation Optionality Revenue Growth Driving Top-Tier Earnings Outlook Screen and identify high-titer RSV plasma donors Hyperimmune donors with sufficient antibodies to select pathogens are
identified Tailoredcompositions Tailored plasma poolsare derived from a unique blend of normal source plasma and plasma obtained from the selected donors Proprietarytesting A proprietary microneutralization assay quantitatively measures
titer levels of neutralizing RSV antibodies in plasma donor samples 5 Upwardly Revised 2024 Guidance: $MM Upwardly Revised 2025 Guidance: (1) Adjusted EBITDA is a non-GAAP financial measure. For a reconciliation of Adjusted EBITDA to
the most comparable GAAP measure, please see the Company’s earnings releases and SEC filings (2) Adjusted Net Income is a non-GAAP financial measure. For a reconciliation of Adjusted Net Income to the most comparable GAAP measure, please see
the Company’s earnings releases and SEC filings
Commercial Opportunities: PLASMA PRODUCTS PORTFOLIO NASDAQ: ADMA
Plasma Therapeutics Introduction to Plasma-Derived Therapies and
Immunoglobulins (IG) ADMA’s optimized IG manufacturing process supports the potential to maximize revenue from each liter of plasma while producing life-sustaining and saving therapies Plasma-derived therapeutics are
essential,life-sustaining biologic drugs that replace absent proteins due to genetic and acquired disorders in hundreds of thousands of patients in the U.S. Many of these naturally occurring proteins are unable to be replaced by new,
innovative therapies Many patients require long-term treatments and some potentially for their entire life Immunoglobulins (IG) or Intravenous Immune Globulins (IVIG) are pooled plasma-derived products from healthy plasma donors,
containing a range of polyclonal antibodies against common pathogens (e.g., bacteria, fungi and viruses) Only 6 companies currently produce IVIG approved for the U.S. market, including CSL Behring, Grifols, Takeda, Octapharma, BPL and
ADMA Other therapeutic products made from plasma proteins include: albumin, coagulation factors, alpha-1 and C-1 esterase, among others 45% Red and white Blood Cells and
Platelets 55% Plasma 90% Water 7% Protein 3% Others 60% Albumin 15% IgG 24% Others 1% Factor VIII Immunoglobulins (IG)
IG Market Is Sizeable & Growing Current $10.5Bn U.S. IG market expected to
grow to $20Bn+ by 2030 Aging Population Geriatric population more susceptible to rare diseases treatable by IG products Global population of 65+ expected to nearly double by 2050 Rise of Use of IGs in Medicine Surge in awareness related
to treatment of rare diseases with IG products Widening scope of indications treatable with IG products Improved Diagnostics Improvements in diagnostics leading to increased rates of PI diagnoses Condition remains under-diagnosed;
average PI diagnosis still takes 12.4 years Increased Use of Immunosuppressive Therapeutics Increased utilization of immuno-oncology agents and other immunosuppressive therapeutics necessitating antibody supplementation Increase in Number
of Plasma Collection Centers Growing number of plasma collection centers worldwide Increase in public and private associations that spread awareness and information related to plasma collection Drivers of IG Market Growth Source:
Marketing Research Bureau, 2022 U.S. Fractionation Market Report, ADMA internal analysis 1. The Plasma Proteins Market In The United States 2022, Marketing Research Bureau Inc., October 2022 2. U.S. IG Market Share by Revenue according to
IQVIA (Sept. 2022) $Bn ADMA’s peak production capacity could garner a ~1.5-2.5%+ share of the market at scale ~$10.5Bn U.S. IG Market in2022 Set to Grow to $20Bn+(1) Market Share of U.S. IG Producers(2) ‘15-22 CAGR 12%
In a 40 year study of 473 patients with PI on standard IVIG (3) Potential
Higher-Risk Target Populations (1) Despite Decades of IG Use, Improved Therapies Still Needed PI is a class of inherited genetic disorders that causes an individual to have a deficient or absent immune system due to either a lack of
necessary antibodies or a failure of these antibodies to function properly Estimated prevalence of 1:1,200 in the U.S., or approximately 250,000 people NIH estimates 500,000 undiagnosed PI patients in the U.S. Over 400 genetic defects are
responsible for PI Patients typically receive monthly outpatient infusions of IVIG therapy Without this exogenous antibody immune support, these patients would be susceptible to a wide variety of infectious diseases ~10% Volume Growth
Projected for IG to Treat PI (6) Primary Immunodeficiency is a Significant Market Opportunity Primary Immunodeficiency (PI) Overview (1) Class Est. Incidence (U.S.) Est. Prevalence Common variable immune deficiency (CVID) 1 in 25,000
to 1 in 50,000 2,000 to 5,000 patients Severe combined immune deficiency (SCID) syndrome ~100 new cases each year 500-1,000 patients on IVIG post-transplant Wiskott-Aldrich syndrome (WAS) ~4 in every 1,000,000 males 600 patients on
IVIG therapy DiGeorge syndrome (DGS) 1 in 4,000 births 1,000 patients on IVIG therapy Ataxia telangiectasia (AT) 1 in 40,000 to 1 in 100,000 3,000 to 8,000 patients X-linked hyper IgM deficiency (XHMD) 2 in every 1,000,000 males 350
patients on IVIG therapy X-linked agammagobulinanemia (XLA) 1 in 10,000 3,500 patients more susceptible to viral infections Source: ADMA information, on file, AAAAI, FDA, Product prescribing information, United Healthcare, Aetna, L.E.K.
Consulting research and analysis Despite standard IG therapy, patients continue to experience recurrent respiratory infection and chronic lung disease (2)(3) 90% developed chroniclung disease (5) developed bronchiectasis (5) PI is a
prevalent and under-diagnosed disorder long-treated with IG therapy,but a continual need for improved options remains experienced recurrent respiratory tract infection (4) 29% 11% 2015 ‒ 2017 IG Volume Growth By Indication 2020 ‒ 2030 IG
Volume Growth By Indication 1. Centers for Disease Control, National Institute of Health 2. The broad spectrum of lung diseases in primary antibody deficiencies. Eur Respir Rev. 2018. 3. Morbidity and mortality in common variable immune
deficiency over 4 decades. 4. The lung in primary immunodeficiencies: New concepts in infection and inflammation. Front Immunol. 2018. 5. Subclinical infection and dosing in primary immunodeficiencies. Clin Exp Immunol. 2014. 6. Wall
Street research
ASCENIVTM Overview THE PRODUCTION OF ASCENIV ONLY IVIG PRODUCT MANUFACTURED
USING PATENTED DONOR SCREENINGAND PLASMA POOLING METHODS (1) IN A 1-YEAR STUDY OF PATIENTS WITH PI, ASCENIV reported zero serious bacterial infections (SBIs)* * SBIs were defined as a rate of <1.0 cases of bacterial pneumonia,
bacteremia/septicemia, osteomyelitis/septic arthritis, visceral abscess and bacterial meningitis per person-year PPPY = per patient per year. Patients and physicians can count on ASCENIV to reduce infection-related quality-of-life
impact Zero hospitalizations due to infection One patient from the study group was hospitalized because of a postoperative local wound infection from elective surgery <1 unscheduled medical visits PPPY 24 out of 59 patients (41%) had a
total of 54 unscheduled medical visits due to infections 1.7 missed days of work / school / activity PPPY due to infection 23 patients (39%) had a total of 93 missed days of work / school / activity due to infections out of a total of
21,535 patient days (<0.5%) 32.9 days of antibiotic use PPPY 37 patients (63%) used antibiotics due to infection (includes therapeutic use) Potential additional target populations across patients at risk for RSV infection,including in
organ transplants and chemotherapy Unique IVIG with differentiation based on patented methods for donor selection and pooling process blending normal source and hyperimmune RSV plasma Indicated for the treatment of patients with primary
immunodeficiency (PI) ADMA received FDA approval in April 2019 and recorded first commercial sale inOctober 2019 Approved and introduced in April 2019 by ADMA 1. ADMA Biologics patents issued 9,107,906 – 9,714,283 – 9,815,886 2.
ASCENIV Prescribing Information, ADMA Biologics, 2019 Plasma pool is derived from a minimum of 1,000 unique donors and blends normal source plasma with RSV plasma Manufactured through a patented process using source plasma, which is
acquired from donors screened using a microneutralization assay to detect and identify which donors possess naturally occurring neutralizing antibody titers to respiratory syncytial virus (RSV) Plasma collected from U.S. FDA-licensed plasma
collection centers Meets potency requirements for 21CFR640 ASCENIV: FDA-Approved Protection Against Serious Infections Proven Efficacy in Treating Patients with PI (2)
BIVIGAM® Overview The Reintroduction of BIVIGAM RESULTS FROM ADMA’S STRONG
EXECUTION AND REGULATORY EXPERTISE IN A 1-YEAR STUDY OF PATIENTS WITH PI, BIVIGAM met all primary endpoints (1)(2) * Target was 1 SBI / year; 99% CI of 0.136 SBI / patient/year; of 63 adult patients in the enrolled in the study, 58 were
included in efficiency analysis PPPY= per patient per year. Demonstrated protection from serious bacterial infections (SBIs) 0.037 rate of SBIs per year* During the 12-month study period, 2 serious acute bacterial infections occurred in
2 patients with an onset date between the first infusion of BIVIGAM and the first follow-up visit 197 total infections in 58 patients were reported (3.7 infections PPPY) 86% of patients were administered antibiotics (39.1 days
PPPY) Reduced health-related burdens Low rate of hospitalizations (0.21 days / PPPY) 2 patients (3.4%) hospitalized for a total of 11 days (0.06%) Fewer missed days of school / work (2.3 days / PPPY) 21 patients (36%) with total of 122
days (0.6%) ADMA acquires Boca Raton manufacturing facility and all rights to BIVIGAM and Nabi-HB June 2017 ADMA works diligently to optimize production processes and bring the facility into FDA compliance; achieved VAI status FDA
Compliance July 2018 ADMA obtains FDA approval for manufacturing BIVIGAM; first commercial sales in August 2019 May 2019 Ongoing reintroduction of BIVIGAM well-received in a high-demand IG market Plasma-derived IVIG that contains a
broad range of antibodies similar to those found in normal human plasma Indicated for the treatment of patients with primary immunodeficiency (PI) ADMA received FDA approval for manufacturing BIVIGAM in May 2019 and recorded first
commercial sale in August 2019 Approved and Reintroduced in May 2019 by ADMA Production of BIVIGAM is voluntarily suspended by previous owner due to manufacturing and compliance issues Production Suspended Dec 2016 1. BIVIGAM
Prescribing Information. Boca Raton, FL: ADMA Biologics; 2019 2. A new intravenous immunoglobulin (BIVIGAM) for primary humoral immunodeficiency. Expert Rev Clin Immunol. 2014. FDA Biologics inspection completed; achieved VAI status
Aug 2021 FDA Compliance BIVIGAM: FDA-Approved Protection Against Serious Infections Proven Efficacy in Treating Patients with PI
Nabi-HB® Overview THE THREAT OF HEPATITIS B NABI-HB PROVIDES PROTECTION
AGAINST HEPATITIS B INFECTION WITHIN 24 HOURS OF ADMINISTRATION (7) Anti-HBs = anti-hepatitis B surface antibodies; IU = international units; WHO = World Health Organization; HBIG = hepatitis immunoglobulin; HBV = hepatitis B virus;
HIV=human immunodeficiency virus. Highly protective potency with Nabi-HB (7) Each milliliter of Nabi-HB contains >312 IU/mL of anti-HBs The potency of each milliliter of Nabi-HB exceeds the potency of anti-HBs in a U.S. reference
hepatitis B immune globulin The U.S. reference has been tested against the WHO standard and found to be equal to 208 IU/mL Established brand and distribution channels driving increased utilization in PEP and sexual assault
patients Successfully used for over 20 years to protect against hepatitis B infection among newly exposed individuals (post-exposure prophylaxis PEP) Manufactured from plasma obtained from vaccinated donors with high titers of antibodies
to hepatitis B surface antigen, anti-HBs Received FDA approval in March 1999 under Nabi Biopharma; recorded first commercial sale under ADMA in April 2018 Approved in March 1999 (via Nabi); marketed by ADMA beginning in June 2017 Delivers
highly effective protection (7) Nabi-HB is 75% effective in preventing an HBV carrier state in those at risk following sexual exposure to persons with acute hepatitis B If administered as a single dose within 2 weeks of exposure EFFICACY
WHEN ADMINISATERED AS A SINGLE DOSE WITHIN 2 WEEKS OF EXPOSURE 75% Effective CDC Recommendations for Prophylaxis: Administering an HBIG with the HBV vaccine series is highly effective in preventing transmission following exposure to HBV
(1) The HBV vaccine series alone takes up to 2 weeks to achieve initial serum levels and 3 doses (across 6 months) to provide seroprotection in ~90% of patients (1)(5)(6) Waning antibody levels may compromise seroprotection over time Among
immunocompetent HBV vaccine responders, protection lasts 15 to 20 years (1) ~67% of U.S. adults 19-49 years old do not have adequate HBV vaccination coverage (1) HBV is 50-100x more infectious than HIV (1) The risk of blood-borne
infections being transmitted after a sexual assault is greater than with consensual sex (1)(2) Incidence of HBV exposure during sexual assault is unknown since the HBV status of perpetrators is rarely known (3) Once someone is exposed to
HBV, it may take hold and develop into potentially deadly chronic liver disease (4) Poses An Immediate Threat to Sexual Assault Patients Seroprotection Remains a Serious Issue Nabi-HB: FDA-Approved for Enhanced Immunity Against Hepatitis-B
Proven Efficacy in Treating Hepatitis B 1. Centers for Disease Control and Prevention. 2. Middlesex-London Health Unit. Post exposure management: hepatitis B, hepatitis C and HIV 3. Roberts and Hedges' Clinical Procedures in Emergency
Medicine and Acute Care 4. World Health Organization 5. Do patients who received only two doses of hepatitis B vaccine need a booster? Cleve Clin J Med. 2014 6. PDR: prescriber’s digital reference. Engerix (hepatitis B vaccine recombinant)
drug summary 7. Data on file. ADMA Biologics
ADMA’s Patented Immunotechnology is Used to Manufacture ASCENIV™ PATENTS
ISSUED 9,107,906 - Composition 9,714,283 - Use 9,815,886 - Methods Expiration 2035 *These patents include the use of IG for treatment and prevention of all viral induced respiratory infections 17
Commercialization/Distribution Strategy for ADMA’s Immunoglobulins Identified
and engaged with appropriate channel partners that align with our call planand sites-of-service where there is demand across our immunoglobulin portfolio Distribution channel is well-defined Inpatients – hospital based Outpatients –
infusion center / physician office / homecare Well established distribution organizations handle cold-chain products efficiently Have existing product serialization tracking systems Have existing relationships with hospital pharmacy buyers
and infusion center/homecare purchasing departments ADMA’s product portfolio offerings have overlapping prescriber call points Clinical immunologists Infectious diseases Hematology/oncology Critical care & emergency
medicine HOSPITALPHARMACY TIER ONE INSTITUTIONS INDEPENDENTINFUSION CENTERS HOME CARE COMPANIES INDEPENDENT GPOs EMERGENCY MEDICINE INFECTIOUS DISEASE CLINICAL IMMUNOLOGY HEMATOLOGY/ONCOLOGY
Plasma Product Manufacturing Overview PRODUCTION OF PLASMA-DERIVED
THERAPIES NASDAQ: ADMA
Fractionation plants are scarce with only a few companies operating FDA approved
facilities in the U.S. World-class, cGMP-compliant plasma fractionation facility and laboratories in Boca Raton, FL; acquired in June 2017 Last FDA compliance inspection completed in August 2021 One of few FDA-approved fractionation
facilities in the U.S. Annual capacity of up to 600,000 liters, or ~2.4M grams of finished IG, supporting a $380M+ revenue opportunity in 2025 Current Production yield of ~3.5-4 g / L and revenue / liter of $600-$800 Patented
immunotechnology to screen hyperimmune donors, tailor plasma pool compositions and conduct proprietary antibody detection testing Capable of full product transfers as well as initial phase plasma product concept development In-house
fill-finish capabilities following the FDA approval of the SA25 Workcell machine Plasma Intermediates are harvested with each batch of IG produced (e.g., Cryoprecipitate and Fraction V). Potential for up to $20M annual revenue
opportunity ADMA Manufacturing One of Few Manufacturers of Specialty IGs in the U.S.
Production of Plasma-Derived Therapies Approximately 4-6 months – includes all
in-process bulk testing and batch record reviewand release by ADMA and any 3rd parties Cohn-Oncley Cold Ethanol Fractionation Process (Estimated 7-12 Months) End-to-end control of the supply chain and production processes to produce our
productsand leverage our expertise as a CMO for others Donors Plasmapheresis Source plasma for manufacturing Must include a 45 day hold per FDA regulation Raw MaterialCollections 1 Manufacturing Cryoprecipitate Viral inactivation
II+III Paste / IG / IVIG Fraction IV Fraction V Fractionation (upstream) Purification (downstream) Ultra-filtration Final formulation 2 Filling & Packaging Filling into vials Final packaging & labeling Lot #
serialization 3 Release & In-Process Testing ADMAin-house 3rd party labs FDA review of each lot 90 days for certain 3rd party lab release tests 4
Internal fill-finish production capabilities expected to result in: Product
Labeling, Packaging and Serialization SA25 Workcell aseptic fill-finish machine received FDA approval In-house fill-finish capabilities with the FDA approval of theSA25 Workcell In-house specialty team to oversee third-party
operations Potential to improve final product yield and enhance margins, speed and time to release product to market Greater product supply consistency Significantly improved operational efficiencies Significantlyimproved gross
margins In-House Fill-Finish & Contract Manufacturing OpportunitiesFill-Finish, Packaging and Serialization Reducedmanufacturing cycle times Fill-Finish Capabilities SA25 Workcell Machine Brings Fill-Finish Capabilities In-House
Plasma Collection Centers ADMA BIOCENTERS PLASMA COLLECTION NETWORK NASDAQ:
ADMA
ADMA BioCenters Overview10 FDA-Licensed Centers Supporting Plasma
Self-Sufficiency Plasma collection centers are essential to ensure raw material supply to produce IG and other plasma proteins ADMA BioCenters consists of a network of10 FDA-licensed plasma collection centers Growing internal plasma
collections from ADMA’s 10 centers supports plasma supply self-sufficiency, which is further supplemented by third party supply agreements to ensure continuity of patient care ADMA BioCenters collects both hyperimmune and normalsource
plasma In addition to providing plasma supply for ADMA products, collected plasma is sold through supply contracts to leading plasma companies Complete FDA Licensure of all 10 centers supports plasma supply self-sufficiency
Milestones, Corporate and Financial Highlights FINACIAL OVERVIEW NASDAQ: ADMA
Experienced Management Team and Board of Directors NAME SELECTED CURRENT OR
PAST AFFILIATIONS Adam GrossmanFounder, President, CEO & Director Brian Lenz, CPAExecutive Vice President, Chief Financial Officer, GM of BioCenters Dr. Jerrold GrossmanFounder & Vice Chairman Lawrence GuiheenDirector Bryant
FongDirector Steven ElmsChairman Young Kwon, Ph.D.Director Alison FingerDirector
Financial Overview Current Financial Overview Three Months Ended December
31, 2023 Three Months Ended December 31, 2022 Revenues $73.9M $50.0M Gross Profit $31.1M $14.2M Adjusted EBITDA(1) $18.6M ($3.5M) Net Loss ($17.6M) ($12.2M) Adjusted Net Income/(Loss) (2) $8.5M ($12.2M) Cash and cash
equivalents $51.4M $86.5M Total assets $329.2M $348.5M Total liabilities $194.0M $196.5M Total stockholders' equity $135.2M $152.0M Weighted Avg. Diluted Common Shares Outstanding 226.0M 202.8M (1) Adjusted EBITDA is a
non-GAAP financial measure. For a reconciliation of Adjusted EBITDA to the most comparable GAAP measure, please see the Company’s earnings releases and SEC filings (2) Adjusted Net Income is a non-GAAP financial measure. For a reconciliation
of Adjusted Net Income to the most comparable GAAP measure, please see the Company’s earnings releases and SEC filings
Supply Chain &End-to-End Control Execute on supply chain robustness and
establish end-to-end control Advance pre-clinical development of newly introduced S. pneumo hyperimmune globulin Expand BioCenters plasma collection facility network to a total of 10 FDA-licensed centers Utilize strong balance sheet and
forecasted cash flow to opportunistically maximize stockholder value Enhance Biologics production yield, increasing peak production output and earnings potential Sustain industry-leading revenue and earnings growth outlook Complete
enrollment in the ASCENIV pediatric PMC study, potentially expanding label Upcoming Milestones Expand BioCentersCollection Network Enhance BiologicsProduction Yield ASCENIV LabelExpansion Advance S. pneumoPre-Clinical
Dev MaximizeValue Drive GrowthOutlook
Thank You NASDAQ: ADMA